



## **Local Anesthetics:**

- potentiate cytotoxicity of the natural killer cells
- facilitate antigen presentation
- modulate function of neutrophils, macrophages, and dendritic cells


Cata JP, Guerra C, Soto G, Ramirez MF. Anesthesia Options and the Recurrence of Cancer: What We Know so Far?. *Local Reg Anesth.* 2020;13:57-72. Published 2020 Jul 7. doi:10.2147/LRA.S240567

























			No. deaths/No. patients (%)		No. of
		OR (95% CI)	Epidural	Control	trials
Prim or sec endpoint <sup>†</sup>	;	0.60 (0.39 - 0.93)	35/1138 (3.1)	52/1063 (4.9)	10
Published deaths only		0.75 (0.54 - 1.04)	68/3911 (1.7)	85/3855 (2.2)	83
All deaths		0.69 (0.51 - 0.92)	80/3911 (2.0)	122/3855 (3.2)	83
Thoracic		0.64 (0.45 - 0.91)	54/3224 (1.7)	90/3142 (2.9)	72
Lumbar —		0.39 (0.10 - 1.58)	2/206 (1.0)	6/217 (2.8)	8
Abdominal		0.73 (0.35 - 1.52)	12/1029 (1.2)	17/1031 (1.6)	35
Cardiac		0.65 (0.38 - 1.12)	21/1304 (1.6)	44/1357 (3.2)	21
Thoracotomy -	<b>.</b>	0.66 (0.28 - 1.53)	10/567 (1.8)	14/498 (2.8)	10
Vascular —		0.39 (0.17 - 0.88)	9/353 (2.5)	16/304 (5.3)	10
 Other (Gyn, Uro, Orth) -		0.89 (0.23 - 3.35)	4/211 (1.9)	5/224 (2.2)	6
All except cardiac		0.71 (0.51 - 1.01)	60/2681 (2.2)	78/2560 (3.0)	62
<3 months	-	0.83 (0.58 - 1.19)	58/2998 (1.9)	68/2944 (2.3)	67
<6 months	- <b></b>	0.74 (0.53 - 1.04)	64/3447 (1.9)	84/3383 (2.5)	79
<12 months		0.69 (0.51 - 0.95)	71/3866 (1.8)	96/3759 (2.6)	82
D. LA		0.61 (0.31 - 1.19)	15/765 (2.0)	23/761 (3.0)	20
LA + opioids		0.63 (0.43 - 0.93)	41/2699 (1.5)	73/2653 (2.8)	62
Low quality		0.70 (0.42 - 1.14)	26/1310 (2.0)	49/1336 [3.7]	34
High quality		0.68 (0.48 - 0.98)	54/2601 (2.1)	73/2519 (2.9)	49
Favo	ors epidural Favors contr	ol			
0.1	1	10			
	Odds ratio				
































Тур	e of Cancer	Author (Year)	Type of Study	Intervention	Overall Survival	Recurrence-Free Surviv
Colo	prectal	Cummings (2012) <sup>61</sup>	Retrospective	EA-GA vs GA	No difference	Increased with GA-EA
Cold	prectal	Gottschalk (2010) <sup>62</sup>	Retrospective	EA-GA vs GA	Not studied	No difference
Cold	prectal	Gupta (2011) <sup>63</sup>	Retrospective	EA-GA vs Spinal vs GA	Increased for rectal cancer, no difference for colon cancer	Not studied
Cold	prectal	Day (2012) <sup>64</sup>	Retrospective	EA-GA vs Spinal vs GA	No difference	No difference
Colo	prectal	Kim (2016) <sup>65</sup>	RCT	LA wound infiltration vs IVPCA	Not studied	No difference
	orectal liver astasis	Zimmitti (2016) <sup>66</sup>	Retrospective	EA-GA vs GA	No difference	Increased with EA-GA
	orectal liver astasis	Gao (2019) <sup>67</sup>	Retrospective	EA-GA vs GA	Not studied	Increased with GA







S							
Type of Cancer	Author (Year)	Type of Study	Intervention	Overall Survival	Recurrence-Free Survival		
Ovarian	De Oliveira (2011) <sup>79</sup>	Retrospective	EA (intra and postop)-GA vs Postop-only EA vs IVPCA	Not studied	Increased with EA-GA		
Ovarian	Lin (2011) <sup>80</sup>	Retrospective	EA vs GA-IVPCA	Increased with EA	Not studied		
Ovarian	Capmas (2012) <sup>81</sup>	Retrospective	EA vs No EA	No difference	No difference		
Ovarian	Lacassie (2013) <sup>82</sup>	Retrospective	EA vs No EA	No difference	No difference		
Ovarian	Tseng (2018) <sup>83</sup>	Retrospective	EA vs IV-PCA	Increased with EA	Increased with EA		
Ovarian	Zhong (2019) <sup>84</sup>	Retrospective	EA vs GA-IVPCA	No difference	Not studied		
Ovarian	Elias (2015) <sup>85</sup>	Retrospective	EA-GA vs GA	Not studied	No difference		

